A massive explosion struck a biotechnology facility in Shuozhou, Shanxi Province, in northern China, killing at least eight people, according to Chinese state media. The company, Shanyin Jiapeng Bio-Technology, produces various chemicals, including agricultural products and paint. The cause of the blast remains under investigation, and authorities have not provided details on why the company’s legal representative was detained. Xinhua News Agency reported that the individual was “placed under control” while inquiries continue.
State media described emergency responders working amid thick, yellowish smoke as search and rescue crews recovered bodies from deep inside the facility. Officials have suggested that additional victims may still be discovered. The State Council Work Safety Committee has reportedly taken over the investigation, signaling the possibility of national-level scrutiny. China Daily noted that the government has launched a nationwide campaign targeting illegal chemical production sites, though it did not directly connect the initiative to the explosion.
The incident is the latest in a series of deadly industrial and biotech accidents in China. In 2015, a Tianjin warehouse explosion killed 173 people and was linked to unsafe storage of sodium cyanide, resulting in multiple arrests. In 2018, Changsheng Biotechnology administered ineffective vaccines to nearly one million children, sparking public outrage and arrests. More recently, lab accidents, including a Nanjing University of Aeronautics and Astronautics explosion, have highlighted ongoing concerns about chemical and biological safety in the country.
China has also faced international scrutiny over the Wuhan Institute of Virology and its handling of coronaviruses prior to the COVID-19 outbreak, with U.S. intelligence suggesting early infections among lab personnel before the first reported cases in Wuhan.
Subsequent reports documented widespread counterfeit coronavirus vaccines and regulatory failures, resulting in dozens of arrests.
Comments
No comments yet. Be the first to share your thoughts.